The monoclonal antibody Rituximab has been approved for the treatment of non-Hodgkin's lymphoma since 1997, but how Rituximab disposes of the cancerous (and normal) B cells is unknown. Research in a new mouse model reported in The Journal of Experimental Medicine suggests that the drug works by triggering the removal of B lymphocytes by scavenger cells.
Antibodies like Rituximab can remove cells in a variety of ways, including killing cells directly, inducing cell suicide, or triggering killing by other immune cells and molecules. Rituximab binds to CD20, a protein found on the surface of all B lymphocytes. In humans it is difficult to analyze how this leads to the elimination of B lymphocytes as only small numbers of cells can be sampled from the blood.
To mimic the clinical situation, Thomas Tedder and colleagues treated mice with a panel of antibodies specific for mouse CD20 (Rituximab is an antibody that binds to human but not mouse B cells). The antibodies that were effective in removing B cells did so by allowing B cell recognition by specialized 'scavenger' immune cells known as macrophages, which carry antibody receptors on their surface.
Less than half of patients with lymphoma respond to anti-CD20 therapy, so drugs that increase the number of macrophages or levels of antibody receptors might improve the response to Rituximab.
The new insight into how CD20 antibodies remove B cells should allow the design of better therapies not only for lymphoma, but also autoimmune diseases caused by rogue self-reactive B cells (as in rheumatoid arthritis), in which CD20 antibody trials are already underway.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Happiness is an imaginary condition, formerly attributed by the living to the dead, now usually attributed by adults to children, and by children to adults.
-- Thomas Szasz